Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06658067 · ClinicalTrials.gov registry record · NA
Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access
A NA study of Diabetes and Type 2 Diabetes, sponsored by Yale University.
- Recruiting
- Registry status
- NA
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT06658067: Recruiting NA study of Diabetes and Type 2 Diabetes, sponsored by Yale University.
NCT06658067 is a NA study of Diabetes and Type 2 Diabetes that is actively recruiting participants, run by Yale University. The registered enrollment target is 17 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06658067, a NA study of Diabetes and Type 2 Diabetes, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
This non-blinded, non-randomized pre-post study will examine the impact of providing CGM sensors free of charge to adult patients of Fair Haven Community Health Care with poorly controlled type 2 diabetes on glycemic control and quality of life.
Primary Outcome
The IIRS is a useful, easy-to-apply tool that measures the degree of illness-induced disruptions in the 13 different aspects of life. Total score range from 13 (minimal intrusiveness) to 91 (extreme intrusiveness).
Conditions Studied
Interventions
- DEVICE Continuous Glucose Monitor (CGM)
Study Locations (1)
Connecticut
- Fair Haven Community Health Care (FHCHC) - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2024-11-12 |
| Est. Completion | 2026-06 |
| Phase | NA |
What NCT06658067 shows while recruiting
NCT06658067 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Continuous Glucose Monitor (CGM) is the first listed.
NCT06658067 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06658067 about?
NCT06658067 is a clinical study titled "Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access". This non-blinded, non-randomized pre-post study will examine the impact of providing CGM sensors free of charge to adult patients of Fair Haven Community Health Care with poorly controlled type 2 diabetes on glycemic control and quality of life.
What is the current status of trial NCT06658067?
This trial is currently recruiting. It is a NA study. The enrollment target is 17 participants. The study started on 2024-11-12. Estimated completion is 2026-06.
What conditions does trial NCT06658067 study?
This clinical trial studies the following conditions: Diabetes, Type 2 Diabetes, Type 2 Diabetes Mellitus - Poor Control.
What interventions are being tested in trial NCT06658067?
The interventions under investigation include: Continuous Glucose Monitor (CGM) (DEVICE).
Who is sponsoring clinical trial NCT06658067?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06658067 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06658067's enrollment target sits among peer trials
17 317th of 338 higher than 21 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI